New Zealand markets closed

MRNA Jan 2023 310.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.5100-0.4500 (-22.96%)
At close: 11:09AM EDT
Full screen
Previous close1.9600
Open1.5100
Bid1.4600
Ask2.2000
Strike310.00
Expiry date2023-01-20
Day's range1.5100 - 1.5100
Contract rangeN/A
Volume1
Open interest524
  • Motley Fool

    Why Sanofi May Be a Frontrunner in Endemic COVID-19

    Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

  • Motley Fool

    If You Invested $10,000 in Moderna 2 Years Ago, This Is How Much You Would Have Today

    Moderna (NASDAQ: MRNA) was one of the best stocks to own last year as it brought its COVID-19 vaccine to market and generated billions in revenue. The company, which was a bit of an unknown before the pandemic began, has quickly risen in popularity.

  • Motley Fool

    1 Green Flag for Moderna's Fall Vaccine Plan, and 1 Red Flag

    Moderna (NASDAQ: MRNA) took center stage when it launched its coronavirus vaccine about a year and a half ago. Moderna recently reported that its booster candidate offers "superior" performance against the omicron variant.